Adma Biologics (ADMA) Current Leases (2011 - 2025)

Adma Biologics has reported Current Leases for 14 years, with the latest figure at $1.1 million in Q4 2025.

• For the quarter ending Q4 2025, Current Leases fell 10.02% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2025 stood at $1.1 million (down 10.02% YoY), and the FY2025 full-year result was $1.1 million, down 10.02% from the prior year.
• Current Leases for Q4 2025 stood at $1.1 million, down from $1.3 million in the prior quarter.
• The five-year high for Current Leases was $1.3 million in Q3 2025, with the low at $317910.0 in Q1 2021.
• Historically, Current Leases has averaged $898699.1 across 5 years, with a median of $981213.5 in 2023.
• Annual changes were most pronounced in 2022 — Current Leases jumped 105.72% — and 2025, when it decreased 10.02%.
• Adma Biologics' Current Leases stood at $591084.0 in 2021, then soared by 53.11% to $905000.0 in 2022, then grew by 15.47% to $1.0 million in 2023, then rose by 16.56% to $1.2 million in 2024, then retreated by 10.02% to $1.1 million in 2025.
• The last three Current Leases figures came in at $1.1 million (Q4 2025), $1.3 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.